IE
SYRE icon

Israel Englander’s Spyre Therapeutics SYRE Stock Holding History

Israel Englander’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,528
Closed -$181K – 7478
2021
Q4 		$181K Buy
+1,528
New +$241K ﹤0.01% 5981

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Israel Englander's SYRE Position: Q2 2026 in Review

Israel Englander increased its Spyre Therapeutics (SYRE) stake by 34% in Q2 2026, buying an estimated $3.65M and bringing the position to 196,712 shares worth $17.5M. The position accounts for 0.01% of the portfolio, ranked #1750.

Israel Englander first reported a position in SYRE in Q2 2016 and has held it in 30 quarters since. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Israel Englander held 196,712 shares of Spyre Therapeutics worth $17.5M as of Q2 2026.
  • Israel Englander bought 50,073 Spyre Therapeutics shares in Q2 2026, an estimated $3.65M.
  • Spyre Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1750 holding.
  • Israel Englander first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 30 quarters since.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.